Volume 146, Issue 10 pp. 2694-2702
Cancer Epidemiology

Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer

Dana Hashim

Dana Hashim

Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY

Dana Hashim and Amparo G. Gonzalez-Feliciano contributed equally to this workSearch for more papers by this author
Amparo G. Gonzalez-Feliciano

Amparo G. Gonzalez-Feliciano

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Dana Hashim and Amparo G. Gonzalez-Feliciano contributed equally to this workSearch for more papers by this author
Thomas U. Ahearn

Thomas U. Ahearn

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD

Search for more papers by this author
Andreas Pettersson

Andreas Pettersson

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Search for more papers by this author
Lauren Barber

Lauren Barber

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Search for more papers by this author
Claire H. Pernar

Claire H. Pernar

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Search for more papers by this author
Ericka M. Ebot

Ericka M. Ebot

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Search for more papers by this author
Masis Isikbay

Masis Isikbay

Department of Surgery, University of California, San Francisco, San Francisco, CA

Search for more papers by this author
Stephen P. Finn

Stephen P. Finn

Department of Histopathology, St. James's Hospital and Trinity College Dublin Medical School, Dublin, Ireland

Search for more papers by this author
Edward L. Giovannucci

Edward L. Giovannucci

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA

Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Search for more papers by this author
Rosina T. Lis

Rosina T. Lis

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Search for more papers by this author
Massimo Loda

Massimo Loda

Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Search for more papers by this author
Giovanni Parmigiani

Giovanni Parmigiani

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

Search for more papers by this author
Tamara Lotan

Tamara Lotan

Department of Pathology, Johns Hopkins Bayview Medical Center, Baltimore, MD

Search for more papers by this author
Philip W. Kantoff

Philip W. Kantoff

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Search for more papers by this author
Lorelei A. Mucci

Lorelei A. Mucci

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Search for more papers by this author
Rebecca E. Graff

Corresponding Author

Rebecca E. Graff

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

Correspondence to: Rebecca E. Graff, Department of Epidemiology & Biostatistics, University of California, San Francisco, Mission Hall: Global Health & Clinical Sciences Building, 550 16th Street, 2nd Floor, Box #0560, San Francisco, CA 94158, Tel.: (510) 847-7060, E-mail: [email protected]Search for more papers by this author
First published: 18 July 2019
Citations: 4
Conflict of interest: P.W.K. does not have a conflict of interest, but it is his policy to report any and all disclosures as an author on a paper. To that end, as of July 10, 2019, he reports the following disclosures for the last 24-month period: he has investment interest in Context Therapeutics LLC, DRGT, Placon, Seer Biosciences, and Tarveda Therapeutics; he is a company board member for Context Therapeutics LLC; he is a consultant/advisory board member for Bavarian Nordic Immunotherapeutics, DRGT, GE Healthcare, Janssen, New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics, and Thermo Fisher; and he serves on data safety monitoring boards for Genentech/Roche and Merck. All other authors have no potential conflicts of interest to disclose.

Abstract

Family history is among the strongest known risk factors for prostate cancer (PCa). Emerging data suggest molecular subtypes of PCa, including two somatic genetic aberrations: fusions of androgen-regulated promoters with ERG and, separately, phosphatase and tensin homolog (PTEN) loss. We examined associations between family history and incidence of these subtypes in 44,126 men from the prospective Health Professionals Follow-up Study. ERG and PTEN status were assessed by immunohistochemistry. Multivariable competing risks models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between self-reported family history of PCa and molecular subtypes of disease. Thirteen percent of men had a positive family history of PCa at baseline. During a median follow-up of 18.5 years, 5,511 PCa cases were diagnosed. Among them, 888 were assayed for ERG status (47% ERG-positive) and 715 were assayed for PTEN loss (14% PTEN null). Family history was more strongly associated with risk of ERG-negative (HR: 2.15; 95% CI: 1.71–2.70) than ERG-positive (HR: 1.49; 95% CI: 1.13–1.95) disease (pheterogeneity: 0.04). The strongest difference was among men with an affected father (HRERG-negative: 2.09; 95% CI: 1.64–2.66; HRERG-positive: 1.30; 95% CI: 0.96–1.76; pheterogeneity: 0.01). Family history of PCa was positively associated with both PTEN null (HR: 2.10; 95% CI: 1.26–3.49) and PTEN intact (HR: 1.72; 95% CI: 1.39–2.13) PCa (pheterogeneity: 0.47). Our results indicate that PCa family history may be positively associated with PCa in all ERG and PTEN subtypes, suggesting a role of genetic susceptibility in their development. It is possible that ERG-negative disease could be especially associated with positive family history.

Abstract

What's new?

Family history is among the strongest known risk factors for prostate cancer (PCa). Despite progress in defining molecular subtypes of PCa, little is known about their heritability. Here, the authors examine associations between family history and incidence of PCa defined by fusions of androgen-regulated promoters with ERG and, separately, PTEN loss in 44,126 men from the prospective Health Professionals Follow-up Study. The results indicate that family history may be positively associated with PCa in all ERG and PTEN subtypes, suggesting a role for genetic susceptibility in their development. Furthermore, ERG-negative disease could potentially be especially associated with positive family history.

Data availability

The data that support the findings of our study are available on request. The data are not publicly available due to privacy or ethical restrictions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.